Abstract
Tacrolimus, also known as FK-506, is produced by Streptomyces tsukubaensis and was discovered in Japan in 1984. The major target of tacrolimus is the T lymphocyte, by inhibiting T cell activation and cell proliferation via suppressing production of growth factor interleukin 2 (IL-2) and subsequent downregulation of IL-2 receptor on cell surface. T cells become activated following ligation of the T cell receptor (TCR) in the immunological synapse generated by receptor-ligand interactions including MHC molecules and co-accessory molecules on antigen-presenting cells (dendritic cells, macrophages and B cells). Subsequent signalling events in T cells include activation of cytoplasmic calcineurin. Calcineurin dephosphorylates and activates the transcription factor NF-AT, which regulates the production of proteins required for T cell activation and differentiation, e.g. cytokines, in particular IL-2. This process can be inhibited by blocking the phosphatase activity of calcineurin by a complex consisting of tacrolimus bound to the immunophilin protein FKBP12 (FK-506 binding protein). This mechanism of action is similar to cyclosporine A with the only difference being the cytoplasmic binding partner. In addition to the inhibition of T cell signalling, tacrolimus appears to affect dendritic cell function by interfering with MHC class II-restricted antigen presentation after binding to another FKBP. There are various isoforms of FKBP with a cell type-specific expression pattern, which might also explain the side effect profile of tacrolimus.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Figueroa MS, Ciancas E, Orte L (2007) Long-term follow-up of tacrolimus treatment in immune posterior uveitis. Eur J Ophthalmol 17:69–74
Fujino Y, Chan CC, de Smet MD et al (1991) FK 506 treatment of experimental autoimmune uveoretinitis in primates. Transplant Proc 23:3335–3338
Hogan AC, McAvoy CE, Dick AD et al (2007) Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology 114:1000–1006
Imai A, Sahara H, Tamura Y et al (2007) Inhibition of endogenous MHC class II-restricted antigen presentation by tacrolimus (FK506) via FKBP51. Eur J Immunol 37:1730–1738
Ishioka M, Ohno S, Nakamura S et al (1994) FK506 treatment of noninfectious uveitis. Am J Ophthalmol 118:723–729
Kawashima H, Fujino Y, Mochizuki M (1988) Effects of a new immunosuppressive agent, FK506, on experimental autoimmune uveoretinitis in rats. Invest Ophthalmol Vis Sci 29:1265–1271
Kilmartin DJ, Forrester JV, Dick AD (1998) Tacrolimus (FK506) in failed cyclosporin A therapy in endogenous posterior uveitis. Ocul Immunol Inflamm 6:101–109
Kino T, Hatanaka H, Hashimoto M et al (1987) FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo) 40:1249–1255
Kitahara K, Kawai S (2007) Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis. Curr Opin Rheumatol 19:238–245
Lee RW, Greenwood R, Taylor H et al (2012) A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in non-infectious uveitis. Ophthalmology 119:1223–1230
Liversidge J, Thomson AW, Forrester JV (1991) FK 506 modulates accessory cell adhesion molecule expression and inhibits CD4 lymphocyte adhesion to retinal pigment epithelial cells in vitro: implications for therapy of uveoretinitis. Transplant Proc 23:3339–3342
Miyata S, Ohkubo Y, Mutoh S (2005) A review of the action of tacrolimus (FK506) on experimental models of rheumatoid arthritis. Inflamm Res 54:1–9
Mochizuki M, Ikeda E, Shirao M et al (1992) Preclinical and clinical study of FK506 in uveitis. Curr Eye Res 11(Suppl):87–95
Mochizuki M, Masuda K, Sakane T et al (1991) A multicenter clinical open trial of FK 506 in refractory uveitis, including Behcet’s disease. Japanese FK 506 Study Group on Refractory Uveitis. Transplant Proc 23:3343–3346
Mochizuki M, Masuda K, Sakane T et al (1993) A clinical trial of FK506 in refractory uveitis. Am J Ophthalmol 115:763–769
Murphy CC, Greiner K, Plskova J et al (2005) Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol 123:634–641
Ni M, Chan CC, Nussenblatt RB et al (1990) FR900506 (FK506) and 15-deoxyspergualin (15-DSG) modulate the kinetics of infiltrating cells in eyes with experimental autoimmune uveoretinitis. Autoimmunity 8:43–51
Oh-i K, Keino H, Goto H et al (2007) Intravitreal injection of Tacrolimus (FK506) suppresses ongoing experimental autoimmune uveoretinitis in Rats. Br J Ophthalmol 91:237–242
Oh-i K, Keino H, Goto H et al (2007) Upregulation of neurotrophic factor-related gene expression in retina with experimental autoimmune uveoretinitis by intravitreal injection of tacrolimus (FK506). Br J Ophthalmol 91:1537–1540
Ruhlmann A, Nordheim A (1997) Effects of the immunosuppressive drugs CsA and FK506 on intracellular signalling and gene regulation. Immunobiology 198:192–206
Sackett DL, Rosenberg WM, Gray JA (1996) Evidence based medicine: what it is and what it isn’t. BMJ 13:71–72
Sakurai E, Nozaki M, Okabe K et al (2003) Scleral plug of biodegradable polymers containing tacrolimus (FK506) for experimental uveitis. Invest Ophthalmol Vis Sci 44:4845–4852
Sloper CM, Powell RJ, Dua HS (1999) Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology 106:723–728
Undre NA (2003) Pharmacokinetics of tacrolimus-based combination therapies. Nephrol Dial Transplant 18(Suppl 1):12–15
U.S. Food and Drug Administration (FDA) Safety Information and Adverse Event Reporting Program (MedWatch) (2006) Medical product safety information. http://www.fda.gov/MedWatch/SAFETY/2006/Apr_PIs/Prograf_PI.pdf
Wallemacq PE, Reding R (1993) FK506 (tacrolimus), a novel immunosuppressant in organ transplantation: clinical, biomedical, and analytical aspects. Clin Chem 39:2219–2228
Webster AC, Woodroffe RC, Taylor RS et al (2005) Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 331:810–820
Whitcup SM, Pleyer U, Lai JC et al (1998) Topical liposome-encapsulated FK506 for the treatment of endotoxin-induced uveitis. Ocul Immunol Inflamm 6:51–56
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Greiner, K., Dick, A.D. (2016). Tacrolimus. In: Zierhut, M., Pavesio, C., Ohno, S., Orefice, F., Rao, N. (eds) Intraocular Inflammation. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-75387-2_31
Download citation
DOI: https://doi.org/10.1007/978-3-540-75387-2_31
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-75385-8
Online ISBN: 978-3-540-75387-2
eBook Packages: MedicineMedicine (R0)